Anita A Mathias - Department of Clinical Pharmacology, Gilead Sciences, Inc

基本信息

浏览量：65

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 141 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Phase 1 Studies to Assess Inhaled Seralutinib As a Perpetrator or a Victim of Drug-Drug Interactions in Healthy Participants

Jianke Li,Ed Parsley,Matt Cravets, Emanuel Denoia,Cassandra Key,Anita Mathias

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENTno. 2 (2025): 91-104

引用0浏览0WOS引用

PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA

C. Soussain,C. Grommes, R. Ward, C. Peterson, M. Cravets,A. Mathias, J. Sosa,B. Kirby, Z. Ding,I. Yusuf,M. Rose, M. Steinberg,H. Tun

HemaSphere（2022）

引用0浏览0引用

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

Brian J. Kirby,Richard Aranda,Renee Ward,Marcos W. Steinberg, Maria Hernandez,Judith Sosa,Matt Cravets,Mark J. Rose,Robin Osterhout,Zhaoqing Ding,Isharat Yusuf,Judith Fox,Anita Mathias

Blood（2022）

引用0浏览0引用

Exposure‐response Relationships for the Efficacy and Safety of Filgotinib and Its Metabolite GS‐829845 in Subjects with Rheumatoid Arthritis Based on Phase 2 and Phase 3 Studies

Amy Meng,Kacey Anderson,Cara Nelson,Liyun Ni,Shu-Min Chuang, Francesco Bellanti, Peter Chang,Craig Comisar,Brian P. Kearney,Beatrix Bartok,Anita Mathias

British Journal of Clinical Pharmacology（2022）

引用5浏览0WOS引用

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Carole Soussain,Samar Issa,Katharine L. Lewis,Christian Grommes,Judith Fox,Renee Ward, Caryn Peterson,Matt Cravets,Anita Mathias,Judith Sosa,Brian J. Kirby,Zhaoqing Ding,Isharat Yusuf,Mark J. Rose,Marcos W. Steinberg,Han W. Tun

Blood（2022）

引用1浏览0引用

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)

Carole Soussain,Christian Grommes,Samar Issa,Renee Ward, Caryn Peterson,Matt Cravets,Anita Mathias,Judith Sosa,Brian Kirby,Zhaoqing Ding,Isharat Yusuf,Mark Rose,Marcos Steinberg,Han W Tun

Neuro-Oncology Advances（2022）

引用0浏览0引用

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

Humeniuk Rita,Mathias Anita,Kirby Brian J.,Lutz Justin D.,Cao Huyen,Osinusi Anu,Babusis Darius,Porter Danielle,Wei Xuelian,Ling John,Reddy Y. Sunila,German Polina

Clinical Pharmacokineticsno. 5 (2021): 569-583

引用91浏览0WOS引用

Validation of LC-MS/MS Methods for Determination of Remdesivir and Its Metabolites GS-441524 and GS-704277 in Acidified Human Plasma and Their Application in COVID-19 Related Clinical Studies

Deqing Xiao,Kah Hiing John Ling,Thomas Tarnowski,Rita Humeniuk,Polina German,Anita Mathias, Jasper Chu,Yuan-Shek Chen, Eric van Ingen

ANALYTICAL BIOCHEMISTRY（2021）

引用38浏览0WOS引用

Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients with COVID-19

Justin D. Lutz,Anita Mathias,Polina German,Cheryl Pikora,Sunila Reddy,Brian J. Kirby

Clinical Pharmacology & Therapeuticsno. 4 (2021): 1116-1124

引用24浏览0WOS引用

Phase 1b Study to Investigate the Safety and Tolerability of Idelalisib in Japanese Patients with Relapsed/refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia

Noriko Fukuhara,Tomohiro Kinoshita,Kazuhito Yamamoto,Hirokazu Nagai,Koji Izutsu,Go Yamamoto,Pankaj Bhargava,Nishan Rajakumaraswamy,Rita Humeniuk,Anita Mathias,Guan Xing,Masato Fukui,Kensei Tobinai

JAPANESE JOURNAL OF CLINICAL ONCOLOGY（2020）

引用6浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn